Clinical Trials
23 trialsNCT07539779 2026-04-20
Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis
Nanfang Hospital, Southern Medical University
Phase 2/3 Not yet recruiting
NCT07440290 2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3 Not yet recruiting
NCT03870750 2026-01-12
Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases
Fred Hutchinson Cancer Center
Phase 2/3 Terminated
NCT05786716 2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT05722886 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT05768178 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT05770037 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT05770544 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT06988475 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT06378138 2025-11-21
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2/3 Recruiting
NCT05678621 2024-04-19
RATIONALISE
Monash University
Phase 2/3 Recruiting
NCT06238336 2024-02-02
Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours
Shanxi Bethune Hospital
Phase 2/3 Unknown
NCT02634294 2023-03-16
Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2/3 Completed
NCT05175508 2022-01-03
Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS
The First Affiliated Hospital of Soochow University
Phase 2/3 Unknown
NCT00967343 2021-06-14
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
Kiadis Pharma
Phase 2/3 Terminated
NCT03483194 2020-06-23
REVEH
Weprom
Phase 2/3 Completed
NCT03818334 2019-02-01
Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies
Hospital Israelita Albert Einstein
Phase 2/3 Recruiting
NCT03733340 2018-11-07
Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT00176839 2017-12-05
Stem Cell Transplantation for Hematological Malignancies
Masonic Cancer Center, University of Minnesota
Phase 2/3 Terminated
NCT00469729 2015-07-10
ExCell
Gamida Cell -Teva Joint Venture Ltd.
Phase 2/3 Completed
NCT00165282 2013-11-28
Mindfulness Meditation in Bone Marrow Transplantation
Emory University
Phase 2/3 Completed
NCT00557817 2010-01-11
Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT)
University of Liege
Phase 2/3 Completed
NCT00382759 2009-08-03
Nonmyeloablative Stem Cell Transplant in Elderly
Azienda Ospedaliera San Giovanni Battista
Phase 2/3 Completed